Jon C Rittenberger1, Alexandra Weissman2, Katharyn L Flickinger2, Francis X Guyette2, David Hopkins3, Melissa J Repine2, Cameron Dezfulian4, Ankur A Doshi2, Jonathan Elmer5, Kelly N Sawyer2, Clifton W Callaway2. 1. Robert Packer Hospital Emergency Medicine Residency, Sayre, PA, United States; Geisinger Commonwealth School of Medicine, Scranton, PA, United States; University of Pittsburgh Department of Emergency Medicine, Pittsburgh, PA, United States. Electronic address: Jon.Rittenberger@guthrie.org. 2. University of Pittsburgh Department of Emergency Medicine, Pittsburgh, PA, United States. 3. Geisinger Commonwealth School of Medicine, Scranton, PA, United States. 4. University of Pittsburgh Department of Critical Care Medicine, Pittsburgh, PA, United States. 5. University of Pittsburgh Department of Emergency Medicine, Pittsburgh, PA, United States; University of Pittsburgh Department of Critical Care Medicine, Pittsburgh, PA, United States.
Abstract
BACKGROUND: Hypothermia improves outcomes following ischemia-reperfusion injury. Shivering is common and can be mediated by agents such as dexmedetomidine. The combination of dexmedetomidine and hypothermia results in bradycardia. We hypothesized that glycopyrrolate would prevent bradycardia during dexmedetomidine-mediated hypothermia. METHODS: We randomly assigned eight healthy subjects to premedication with a single 0.4 mg glycopyrrolate intravenous (IV) bolus, titrated glycopyrrolate (0.01 mg IV every 3 min as needed for heart rate <50), or no glycopyrrolate during three separate sessions of 3 h cooling. Following 1 mg/kg IV dexmedetomidine bolus, subjects received 20 ml/kg IV 4 °C saline and surface cooling (EM COOLS, Weinerdorf, Austria). We titrated dexmedetomidine infusion to suppress shivering but permit arousal to verbal stimuli. After 3 h of cooling, we allowed subjects to passively rewarm. We compared heart rate, core temperature, mean arterial blood pressure, perceived comfort and thermal sensation between groups using Kruskal-Wallis test and ANOVA. RESULTS: Mean age was 27 (SD 6) years and most (N = 6, 75%) were male. Neither heart rate nor core temperature differed between the groups during maintenance of hypothermia (p > 0.05). Mean arterial blood pressure was higher in the glycopyrrolate bolus condition (p < 0.048). Thermal sensation was higher in the control condition than the glycopyrrolate bolus condition (p = 0.01). Bolus glycopyrrolate resulted in less discomfort than titrated glycopyrrolate (p = 0.04). CONCLUSIONS: Glycopyrrolate did not prevent the bradycardic response to hypothermia and dexmedetomidine. Mean arterial blood pressure was higher in subjects receiving a bolus of glycopyrrolate before induction of hypothermia. Bolus glycopyrrolate was associated with less intense thermal sensation and less discomfort during cooling.
BACKGROUND: Hypothermia improves outcomes following ischemia-reperfusion injury. Shivering is common and can be mediated by agents such as dexmedetomidine. The combination of dexmedetomidine and hypothermia results in bradycardia. We hypothesized that glycopyrrolate would prevent bradycardia during dexmedetomidine-mediated hypothermia. METHODS: We randomly assigned eight healthy subjects to premedication with a single 0.4 mg glycopyrrolate intravenous (IV) bolus, titrated glycopyrrolate (0.01 mg IV every 3 min as needed for heart rate <50), or no glycopyrrolate during three separate sessions of 3 h cooling. Following 1 mg/kg IV dexmedetomidine bolus, subjects received 20 ml/kg IV 4 °C saline and surface cooling (EM COOLS, Weinerdorf, Austria). We titrated dexmedetomidine infusion to suppress shivering but permit arousal to verbal stimuli. After 3 h of cooling, we allowed subjects to passively rewarm. We compared heart rate, core temperature, mean arterial blood pressure, perceived comfort and thermal sensation between groups using Kruskal-Wallis test and ANOVA. RESULTS: Mean age was 27 (SD 6) years and most (N = 6, 75%) were male. Neither heart rate nor core temperature differed between the groups during maintenance of hypothermia (p > 0.05). Mean arterial blood pressure was higher in the glycopyrrolate bolus condition (p < 0.048). Thermal sensation was higher in the control condition than the glycopyrrolate bolus condition (p = 0.01). Bolus glycopyrrolate resulted in less discomfort than titrated glycopyrrolate (p = 0.04). CONCLUSIONS: Glycopyrrolate did not prevent the bradycardic response to hypothermia and dexmedetomidine. Mean arterial blood pressure was higher in subjects receiving a bolus of glycopyrrolate before induction of hypothermia. Bolus glycopyrrolate was associated with less intense thermal sensation and less discomfort during cooling.
Authors: Koen Ameloot; Cathy De Deyne; Ward Eertmans; Bert Ferdinande; Matthias Dupont; Pieter-Jan Palmers; Tibaut Petit; Philippe Nuyens; Joren Maeremans; Joris Vundelinckx; Maarten Vanhaverbeke; Ann Belmans; Ronald Peeters; Philippe Demaerel; Robin Lemmens; Jo Dens; Stefan Janssens Journal: Eur Heart J Date: 2019-06-07 Impact factor: 29.983
Authors: Jon C Rittenberger; Kathryn L Flickinger; Alexandra Weissman; Melissa Repine; Jonathan Elmer; Francis X Guyette; Clifton W Callaway Journal: Aerosp Med Hum Perform Date: 2019-05-01 Impact factor: 1.053
Authors: Salim S Virani; Alvaro Alonso; Emelia J Benjamin; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Francesca N Delling; Luc Djousse; Mitchell S V Elkind; Jane F Ferguson; Myriam Fornage; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Tak W Kwan; Daniel T Lackland; Tené T Lewis; Judith H Lichtman; Chris T Longenecker; Matthew Shane Loop; Pamela L Lutsey; Seth S Martin; Kunihiro Matsushita; Andrew E Moran; Michael E Mussolino; Amanda Marma Perak; Wayne D Rosamond; Gregory A Roth; Uchechukwu K A Sampson; Gary M Satou; Emily B Schroeder; Svati H Shah; Christina M Shay; Nicole L Spartano; Andrew Stokes; David L Tirschwell; Lisa B VanWagner; Connie W Tsao Journal: Circulation Date: 2020-01-29 Impact factor: 29.690
Authors: Neeraj Badjatia; Evangelia Strongilis; Errol Gordon; Mary Prescutti; Luis Fernandez; Andres Fernandez; Manuel Buitrago; J Michael Schmidt; Noeleen D Ostapkovich; Stephan A Mayer Journal: Stroke Date: 2008-10-16 Impact factor: 7.914
Authors: E Wesley Ely; Brenda Truman; Ayumi Shintani; Jason W W Thomason; Arthur P Wheeler; Sharon Gordon; Joseph Francis; Theodore Speroff; Shiva Gautam; Richard Margolin; Curtis N Sessler; Robert S Dittus; Gordon R Bernard Journal: JAMA Date: 2003-06-11 Impact factor: 56.272
Authors: David Hostler; Jiangquan Zhou; Michael A Tortorici; Robert R Bies; Jon C Rittenberger; Philip E Empey; Patrick M Kochanek; Clifton W Callaway; Samuel M Poloyac Journal: Drug Metab Dispos Date: 2010-02-17 Impact factor: 3.922
Authors: Clifton W Callaway; Jonathan Elmer; Francis X Guyette; Bradley J Molyneaux; Kacey B Anderson; Philip E Empey; Stacy J Gerstel; Kate Holquist; Melissa J Repine; Jon C Rittenberger Journal: PLoS One Date: 2015-08-03 Impact factor: 3.240